Cargando…

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

PURPOSE: New therapies are needed for relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. This phase 1b, open-label trial evaluated two anti-CD20-based triplet combinations. METHODS: Patients with R/R follicular lymphoma (FL; n = 13) were treated with obinutuzumab, atezolizumab, and polatuzumab v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Topp, Max S., Eradat, Herbert, Florschütz, Axel, Hochhaus, Andreas, Wrobel, Tomasz, Walewski, Jan, Knopinska-Posluszny, Wanda, Kanate, Abraham S., Lech-Maranda, Ewa, Brunnberg, Uta, Chitra, Surya, Nielsen, Tina G., Sellam, Gila, Shivhare, Mahesh, Lossos, Izidore S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931830/ https://www.ncbi.nlm.nih.gov/pubmed/35182224 http://dx.doi.org/10.1007/s00432-021-03847-5

Ejemplares similares

Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Polatuzumab vedotin for B-cell lymphoma
Publicado: (2020)

Correction to: Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Excellent Interim Treatment Response with Polatuzumab Vedotin
por: Mehtap, Özgür, et al.
Publicado: (2020)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
por: Alanzi, Meshaal, et al.
Publicado: (2023)

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
por: Lynch, Ryan C., et al.
Publicado: (2022)

Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2018)

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2019)

Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
por: Major, Ajay, et al.
Publicado: (2022)

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma
por: Thomas, Colin, et al.
Publicado: (2023)

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Time‐to‐Event Analysis of Polatuzumab Vedotin‐Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens
por: Lu, D, et al.
Publicado: (2017)

Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients
por: Douglas, Melanie
Publicado: (2020)

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
por: Shemesh, Colby S., et al.
Publicado: (2020)

Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
por: Assi, Rita, et al.
Publicado: (2021)

Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
por: Dere, Randall C., et al.
Publicado: (2023)

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
por: Song, Yuqin, et al.
Publicado: (2023)

Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
por: Anderson, Kara, et al.
Publicado: (2020)

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
por: Northend, Michael, et al.
Publicado: (2022)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?
por: Davis, James A., et al.
Publicado: (2023)

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
por: Gouni, Sushanth, et al.
Publicado: (2022)

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma
por: Terui, Yasuhito, et al.
Publicado: (2021)

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
por: Argnani, Lisa, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY(®)) Antibody–Drug Conjugate in Sprague Dawley Rats
por: Yip, Victor, et al.
Publicado: (2021)

Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin
por: Li, Dongwei, et al.
Publicado: (2019)

A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma
por: Liu, Yanyan, et al.
Publicado: (2022)

Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
por: Saburi, Masuho, et al.
Publicado: (2023)

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
por: Shi, Rong, et al.
Publicado: (2020)

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
por: Dal, Mehmet Sinan, et al.
Publicado: (2022)

Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study
por: Kinoshita, Tomohiro, et al.
Publicado: (2020)

Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
por: Abdur Raqib, Moosa, et al.
Publicado: (2023)

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2020)

P1227: POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY
por: Dal, M. S., et al.
Publicado: (2022)

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
por: Morschhauser, Franck, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mlbkdu6f9inubltdaognto6lk0